Acrivon Therapeutics

Acrivon Therapeutics is a clinical-stage precision oncology company focused on drug development through early clinical treatments. The company specializes in applying its approach to target tumor drug targets that are causally linked to the majority of cancers, particularly those without simple monogenic driver mutations or synthetic lethality. Utilizing its unique precision medicine platform—Acrivon Predictive Precision Proteomics (AP3)—the company develops its drug pipeline.